St. Louis, MO, United States
St. Louis, MO, United States

Time filter

Source Type

News Article | November 8, 2016
Site: www.prnewswire.com

CHESTERFIELD, United Kingdom, Nov. 8, 2016 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has approved a Prior Approval Supplement for OFIRMEV® (acetaminophen)...


News Article | February 15, 2017
Site: www.prweb.com

Patient Safety Awareness Week, a highlight of the United for Patient Safety Campaign, will be observed March 12-18, 2017. Led by the National Patient Safety Foundation (NPSF), a central voice for patient safety since 1997, Patient Safety Awareness Week is time dedicated to raising awareness about patient safety among health care professionals and the public. “We have a lot of exciting activity planned, and we are hoping to see large numbers of health care organizations, health professionals, and members of the public get involved,” said Tejal K. Gandhi, MD, MPH, CPPS, president and chief executive officer, NPSF. “This is a time for all of us to share what we know, learn from others, and celebrate the real victories, large and small, that we’ve seen in patient safety over the past 20 years.” Research suggests that as many as 440,000 patients die each year as a result of preventable medical harm, and that many others suffer significant and lasting morbidity, and quality-of-life implications. Given this evidence, NPSF advocates for addressing patient safety as a serious public health concern. These themes will be addressed during activities planned for the week: NPSF is also urging health professionals and members of the public to take a pledge in support of patient safety. Those wishing to participate in Patient Safety Awareness Week can visit the website, http://www.unitedforpatientsafety.org, to take the pledge, share their plans for the week, get ideas for activities, download campaign materials, or honor a loved one touched by medical harm. NPSF is marking its 20th anniversary in 2017 and this is the 15th year that the organization has led Patient Safety Awareness Week. The Foundation is pleased to recognize Mallinckrodt Pharmaceuticals for their generous support of Patient Safety Awareness Week 2017 and their ongoing commitment to patient and workforce safety. About the National Patient Safety Foundation The National Patient Safety Foundation’s vision is to create a world where patients and those who care for them are free from harm. A central voice for patient safety since 1997, NPSF partners with patients and families, the health care community, and key stakeholders to advance patient safety and health care workforce safety and disseminate strategies to prevent harm. NPSF is an independent, not-for-profit 501(c)(3) organization. For more information visit http://www.NPSF.org.


According to the report, the global Photopheresis Products Market was valued at US$ 223.1 Mn in 2015 and is projected to expand at a CAGR of 5.9% from 2016 to 2024 to reach US$ 371.1 Mn in 2026. This report offers a thorough understanding of the photopheresis products market, its key market trends, drivers, restraints, opportunities, threats, and pricing. Photopheresis is considered as an effective treatment option for various autoimmune diseases, chronic graft versus host disease, solid organ transplant rejections namely liver and kidney and advanced cutaneous T-cell lymphoma. Photopheresis is also known as extracorporeal photoimmunotherapy, which was approved FDA in 1988 as eukapheresis-based therapeutic procedure. With the growing demand for blood derived products, the photopheresis product market is expected to gain a traction during the forecast period. According to World Health Organization (WHO), approximately 5% of global population carries trait genes for blood related disorders each year. Thus rising blood disorders is one of prime factor driving the market growth. Similarly, growing global prevalence of cutaneous T-cell lymphoma is expected to boost the growth for photopheresis market. According to Cutaneous Lymphoma Foundation, the incidence of CTL has been accounted for 1500 new cases each year in U.S. The current treatment for CTL has several side effects, thus, photopheresis therapy is preferred to overcome these side effects due to better safety and efficacy than other drug treatments. Similarly photopheresis is used in a few countries to treat other disease indications such as transplantation rejection conditions and autoimmune diseases. In 2010, the rate of organ transplantation was around 14.9% per million population, which has increased to 16.5% per million population globally. In terms of product type, these are two types of photopheresis systems available in the market, namely open system and closed system. In open ECP systems use separate devices to separate leucocytes from blood and drug photo activation process, whereas, In closed ECP system the cell separation from blood, photoactivation and re-infusion process all takes place in single device. In the global photopheresis products market, closed systems are widely used by the healthcare practitioners as it offers several advantage such as less risk of infection and contamination over open systems. The closed system segment is accounted for major share in global photopheresis market in 2015 accounting for 81.1% and is expected to grow at a fastest CAGR during the forecast period. The technologically advanced system and one-step procedure are few of the key reason for the market growth. However, high cost of closed system might hinder the market growth during the forecast period. Get Exclusive Sample Copy of this Research Insights - http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14771 Although there are some impediments in the market such as unavailability of treatment clinics in developing and under developed regions and high cost ECP therapy. ECP therapies are reimbursed by governments, however, these are still costly even after reimbursement and usually takes longer time to treat and perform. For instance, in the U.S., ECP therapy costs around US $8000 per treatment and every individual has to take the treatment for every two weeks and continue the same procedure for one year to complete the treatment. Developed region such as North America and Europe represent a significant demand for photopheresis, owing to the favorable reimbursement scenario, early adoption of advanced techniques and affordability of advanced treatment options. However, Asia Pacific photopheresis products market is expected to grow at a significant CAGR owing to quick regulatory approvals and growing adoption of advanced treatment options. Key players in this market are as Macopharma , Haemonetics Corporation, Med Tech Solutions GmbH,  Fresenius Kabi AG, Terumo Corporation, and Mallinckrodt Pharmaceuticals among others. The global Photopheresis Products Market has been segmented as follows: Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.


In a small phase I and II clinical trial, Johns Hopkins researchers and colleagues elsewhere found that the high-fat, low-carbohydrate ketogenic diet was a safe and effective treatment option for the majority of adults experiencing a relatively rare, often fatal and always severe form of epilepsy marked by prolonged seizures that require medically induced comas to prevent them from further damaging the body and the brain. In a report on the trials, published online Feb. 8 in Neurology, the investigators conclude that the diet is a "feasible" option for people with so-called super-refractory status epilepticus (SRSE), the most severe seizure classification, in which up to an estimated 60 percent of patients die once they develop this type of seizure. According to the Centers for Disease Control and Prevention, more than 5 million people in the U.S. have a seizure disorder. More than 150,000 people in the U.S. each year will develop refractory status epilepticus and, according to published studies, about half of those will develop super-refractory seizures. "From our past research, we know the ketogenic diet is effective in approximately one-third of adults with epilepsy who are resistant to traditional anti-seizure drugs," says Mackenzie C. Cervenka, M.D., associate professor of neurology and director of the Adult Epilepsy Diet Center at the Johns Hopkins University School of Medicine. "Because there isn't a standard treatment for super-refractory status epilepticus and those patients diagnosed have such a high death and disability rate, we decided we had to try something different to treat them and test its safety and value." For the study, the research team recruited 15 patients hospitalized with super-refractory status epilepticus at The Johns Hopkins Hospital, Mayo Clinic, the Queen's Medical Center in Honolulu and Thomas Jefferson University Hospital in Philadelphia. The patients ranged in age from 18 to 82. Five were men, and six had a previous history of some form of epilepsy prior to developing super-refractory seizures. Super-refractory status epilepticus can occur in people who already have a seizure disorder or in those without such a history. Nine participants were white, four were African-American, one was Asian and one was native Hawaiian. In general, after a patient has experienced 24 hours in a seizure and there have been multiple failed attempts to stop it with drugs, physicians will use general anesthetics to put a patient in a coma to protect the muscles, kidneys and brain from damage -- common side effects of prolonged seizure episodes. After 24 hours, the patient is awakened to see if the seizures return. If so, then the seizures are considered super-refractory. Then, the physician will put the patient back in a coma and continue to try other medications, but there is no standard treatment protocol at this point. Patients in the research population had taken an average of eight anti-seizure medications before physicians introduced a commercially prepared ketogenic diet. The diet contained a nutrient liquid composed of four parts fat to one part carbohydrates and protein combined in grams. Each patient received the diet through a feeding tube over 72 hours, with their calorie needs calculated based on weight, while in a medically induced coma. After 72 hours on the diet, the physicians tapered off their anesthesia to see if the seizures had stopped. If the seizures did not return at this point, patients continued with the diet for several days until they could eat on their own, at which time they were switched to a modified Atkins diet, which is high in fat and low in carbohydrates as well. If a patient's seizures continued, he or she was kept on the feeding tube ketogenic diet, but additional anti-seizure medications were given as well. The rationale for the high-fat ketogenic diet, popularized by neurologists at Johns Hopkins over the past 30 years, is based on the fact that it accelerates the body's metabolism of fats, similar to fasting, which appears to alter the excitability of nerve cells in the brain. When most of a person's calories or energy come from fat, the body accumulates metabolic breakdown products known as ketone bodies. Ketones are easily measured in the blood and urine. After two days, all patients had detectible levels of ketones, showing that they were metabolizing fat -- rather than carbohydrates or proteins -- for cellular energy. One patient among the 15 was taken off the diet when family members requested to withdraw care and died. In 11 of the remaining 14, or 79 percent, who completed the full course of the ketogenic diet, super-refractory seizures stopped, with eight recovering within a week after the episode started. Five patients in the study died, including the one taken off the diet when the family requested withdrawal of care. Three of those who died weren't helped by the ketogenic diet, and the diet was stopped when they developed dangerous acid levels despite treatment with bicarbonate, the standard and best therapy for acidosis in this situation. The fifth patient improved with the ketogenic diet while hospitalized, but the diet was discontinued during rehabilitation in another facility. The super-refractory status epilepticus recurred and was treated anew with the ketogenic diet, but the patient succumbed to a heart attack not likely related to the diet, according to an independent panel. Ten of the 15 patients experienced adverse effects of the diet, which included constipation, weight loss, low blood sugar, high cholesterol in the blood and low sodium levels in the blood. Altogether, six of the 11 patients who completed the ketogenic diet course in the hospital eventually switched to a modified Atkins diet, which is easier to follow than the ketogenic diet. The ketogenic diet requires precise weighing and measurements of food and can be hard to maintain, says Cervenka. The modified Atkins diet limits patients to 20 grams of carbohydrates per day (not including fiber) and allows liberal amounts of fat. At the six-month follow-up for these 11 patients, four were still on the modified Atkins diet. Two patients who remained seizure-free tapered off the diet because they found it difficult to follow. Two patients reported their seizures reduced by more than 50 percent, two had ongoing seizures, one had experienced a single seizure and none experienced return of status epilepticus. The researchers caution that much further research will be need to support the idea that the ketogenic diet should be widely used in those with this severe form of epilepsy. "We can only state that it appears to work in some patients to halt status epilepticus and reduces the frequency of their seizures," says Cervenka. The researchers plan to carry out phase III randomized controlled clinical trials to determine the actual rate of effectiveness by comparing those treated with the ketogenic diet to a group tube-fed a normal, nonketogenic diet. "What we can say is that the ketogenic diet is promising for at least a subset of patients. Any safe means we have of getting patients off of anesthesia and out of a coma quickly will be welcome," says Cervenka. Additional authors on the study include Bobbie Henry-Barron, Eric Kossoff, Adam Hartman, John Probasco, David Benavides, Arun Venkatesan, Batya Radzik, Marie Depew, Filissa Caserta, Paul Nyquist, Romergryko Geocadin and Peter Kaplin of Johns Hopkins Medicine; Sara Hocker of Mayo Clinic in Rochester, Minnesota; Matthew Koenig, Eliza Hagen, Denise Dittrich and Tracy Stern of the Queen's Medical Center in Honolulu; and Barak Bar of Thomas Jefferson University Hospital in Philadelphia. The study was funded by philanthropic gifts from Chris Garrod, Dawn Griffiths and the Carson Harris Foundation. Cervenka receives grants from Nutricia and Vitaflo, and honoraria from the Neurology Center and LivaNova. Hocker consults for SAGE Therapeutics. Henry-Barron receives grants from Nutricia and Vitaflo. Kossoff received a grant from Nutricia and consults for Atkins Nutritionals Inc. Hartman receives royalties from Wiley, LWW and Taylor & Francis, and has a patent pending for a new therapeutic molecule for seizure treatment. Benavides receives funding from Mallinckrodt Pharmaceuticals. Geocadin receives a grants from KeyTech Inc.


MELBOURNE, Australia and NEW YORK, Feb. 26, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with a strategic update, financial results for the half-year period ended December 31, 2016 (half-year FY2017), and operational highlights. Our corporate vision is to bring to market disruptive cellular medicines to treat serious and life-threatening illnesses. We are developing lead product candidates, based on our proprietary mesenchymal lineage cell technology platform, which have shown a strong safety profile and consistent signals of efficacy in difficult to treat patient segments, reflective of the unique mechanisms of action of our cells. To achieve our corporate vision, Mesoblast has prioritized its pipeline to focus its resources on four Tier 1 product candidates that represent the nearest-term revenue opportunities and/or potential blockbuster target markets. These product candidates are well positioned to meet objectives of the recently enacted 21st Century Cures Act.  This Act provides an accelerated approval pathway in the United States, the world’s largest healthcare market, for cell-based medicines designated as regenerative advanced therapies. Mesoblast intends to enter into strategic alliances with partners who share our corporate vision and can leverage their existing strengths and capabilities to maximize the commercial value of our lead assets. In line with this objective, Mesoblast recently entered into a period of exclusivity to negotiate a commercial and development partnership with Mallinckrodt Pharmaceuticals for two Tier 1 product candidates in consideration for an equity purchase of 20 million shares. Mallinckrodt is a global specialty pharmaceutical company with a major focus within the hospital acute and critical care settings, including pain management, autoimmune and rare diseases, and specialty generic pharmaceuticals. At December 31, 2016, the Group had cash reserves of US$55.6 million after adjusting for the committed capital of US$21.7 million from the equity purchase agreement with Mallinckrodt Pharmaceuticals announced on December 23, 2016, the proceeds of which were subsequently received on January 6, 2017. During the half-year FY2017, the Company has executed its planned operational streamlining and re-prioritization of projects to successfully absorb the incremental costs of the MPC-150-IM program in advanced chronic heart failure (CHF).  In line with this objective, operating cash outflows for the half-year FY2017 excluding MPC-150-IM for CHF were reduced by 22% (US$11.5 million) compared with the half-year period ended December 31, 2015 (half–year FY2016).  After absorbing the incremental R&D costs associated with the CHF program, total operating cash outflows were US$47.3 million, still a reduction of 9% (US$4.6 million) compared with the half-year FY2016. The US$11.5 million in savings was achieved principally through reduced spend on commercial manufacturing, labor costs within R&D and management & administration. As previously announced, a fully discretionary equity facility has been established for up to $A120 million/$US90 million over 36 months. 1.  Mesoblast is currently conducting a Phase 3 trial of MPC-150-IM in New York Heart Association (NYHA) Class II-III advanced CHF patients. 2.   MPC-150-IM is also currently being evaluated in a Phase 2b trial in patients with end-stage heart failure who have received a left ventricular assist device (LVAD).  This program is sponsored and funded by the United States National Institutes of Health (NIH). The results of these trials will be used to guide the Company’s discussions with the United States Food and Drug Administration (FDA) in line with the 21st Century Cures Act for potential accelerated approval pathways for MPC-150-IM. Given the serious nature of anti-TNF resistant RA, MPC-300-IV is well-positioned to be developed as a regenerative advanced therapy to target this major unmet medical need. Financial Results for the Six Months Ended 31 December 2016 (the half-year) (in U.S. Dollars) The Company has executed a range of cost reduction initiatives in order to offset the incremental costs of the MPC-150-IM program in FY2017. In line with this objective, operating cash outflows for the half-year FY2017 excluding MPC-150-IM for CHF were reduced by 22% (US$11.5 million) compared with the half-year FY2016. These reductions comprised: $3.4 million within Research and Development; $7.2 million in Manufacturing Commercialization; and $0.9 million within Management and Administration. Loss before income tax for the half-year FY2017 increased by $10.6 million primarily due to non-cash revenue items that do not affect our cash reserves, compared with the half-year FY2016. The main items which impacted the loss before income tax movement were: The overall increase in loss before income tax also includes movements in other items which did not impact our current cash reserves, such as: contingent consideration, finance costs and foreign exchange movements within other operating income and expenses. Our net loss attributable to ordinary shareholders was $39.8 million, or 10.50 cents per share, for the half-year FY2017, compared with $35.5 million, or 10.31 cents per share, for the half-year FY2016. Financial Results for the Three Months Ended 31 December 2016 (second quarter) (in U.S. Dollars) Loss before income tax increased by $0.9 million (4%) for the second quarter of FY2017 compared with the second quarter of FY2016. This overall increase in loss before income tax was primarily impacted by non-cash items that do not affect our cash reserves. From August 2016, the Company executed a range of cost reduction initiatives in order to offset the incremental costs of the MPC-150-IM program in FY2017. Progress on these initiatives is explained above in the Financial Results for the Six Months Ended 31 December 2016 (the half-year). The main items which impacted the loss before income tax movement were as follows: The overall increase in loss before income tax also includes movements in other items which did not impact our current cash reserves, such as: contingent consideration, finance costs and foreign exchange movements within other operating income and expenses. Our net loss attributable to ordinary shareholders was $20.1 million, or 5.27 cents per share, for the second quarter of FY2017, compared with $22.3 million, or 6.29 cents per share, for the second quarter of FY2016. Mesoblast will be hosting a conference call beginning at 9.00am AEDT on February 27, 2017 / 5.00pm EST on February 26, 2017.  The conference identification code is 638112. The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/58af4d2b196ffa2970ec979c To access the call, please dial: This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Maryland Heights, MO, November 30, 2016 --( Visit the Medical Imaging Equipment Market – Product Types (Computed Tomography Scanners, Magnetic Resonance Imaging Equipment, Nuclear Imaging Equipment – PET, SPECT, Ultrasound Systems, X-Ray Devices) and Technologies (Computed Tomography Scanners, Magnetic Resonance Imaging Equipment, Nuclear Imaging Equipment – PET, SPECT, Ultrasound Systems – 2D, 3D, 4D, Doppler, High Intensity Frequency Ultrasound, Lithotripsy, X-Ray Devices – Analog, Computed, Digital Radiography) 2016-2020 report at https://www.ihealthcareanalyst.com/report/medical-imaging-equipment-market/ Medical imaging reagents are chemicals to allow clinicians to improve the imaging of specific organs, tissues, diseases and physiological functions. Medical imaging reagents are specially designed chemical compounds used to enhance images produced through imaging systems. These reagents allow clinicians and healthcare providers to determine whether a tumor is malignant or benign and enables to locate any metastatic cancerous sites in the body. Medical imaging reagents are used for diagnosing disease, monitoring disease progression, tracking therapeutic response, and enhancing our knowledge of physiology and pathophysiology. Medical imaging incorporates radiology which uses the imaging technologies of X-ray radiography, magnetic resonance imaging, medical ultrasonography or ultrasound, endoscopy, elastography, tactile imaging, thermography, medical photography and nuclear medicine functional imaging techniques as positron emission tomography (PET) and Single-photon emission computed tomography (SPECT). Medical imaging reagents play a significant role in diagnostic, pharmaceuticals, biotechnology medical and life science industries. The global medical imaging reagents market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020). The global medical imaging reagents market segmentation is based on product types (contrast reagents, optical reagents, nuclear reagents), technology (fluorescent dyes and probes, fluorescent proteins, nanoparticles, quantum dots, radiopharmaceuticals), and applications (diagnostics, drug discovery and development, research and development). The global medical imaging reagents market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global medical imaging reagents market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global medical imaging reagents market and included in this report are Bayer Healthcare AG, Bracco Imaging SpA, GE Healthcare, Lantheus Medical Imaging, Inc., Mallinckrodt Pharmaceuticals, Siemens Healthcare, Thermo Fisher Scientific, Inc. and others. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/medical-imaging-equipment-market/ About Us iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, November 30, 2016 --( PR.com )-- The global medical imaging reagents market is estimated to reach USD 19.7 Billion in 2020, expanding at a CAGR of 8.5% from 2016 to 2020, published by iHealthcareAnalyst, Inc.Visit the Medical Imaging Equipment Market – Product Types (Computed Tomography Scanners, Magnetic Resonance Imaging Equipment, Nuclear Imaging Equipment – PET, SPECT, Ultrasound Systems, X-Ray Devices) and Technologies (Computed Tomography Scanners, Magnetic Resonance Imaging Equipment, Nuclear Imaging Equipment – PET, SPECT, Ultrasound Systems – 2D, 3D, 4D, Doppler, High Intensity Frequency Ultrasound, Lithotripsy, X-Ray Devices – Analog, Computed, Digital Radiography) 2016-2020 report at https://www.ihealthcareanalyst.com/report/medical-imaging-equipment-market/Medical imaging reagents are chemicals to allow clinicians to improve the imaging of specific organs, tissues, diseases and physiological functions. Medical imaging reagents are specially designed chemical compounds used to enhance images produced through imaging systems. These reagents allow clinicians and healthcare providers to determine whether a tumor is malignant or benign and enables to locate any metastatic cancerous sites in the body. Medical imaging reagents are used for diagnosing disease, monitoring disease progression, tracking therapeutic response, and enhancing our knowledge of physiology and pathophysiology. Medical imaging incorporates radiology which uses the imaging technologies of X-ray radiography, magnetic resonance imaging, medical ultrasonography or ultrasound, endoscopy, elastography, tactile imaging, thermography, medical photography and nuclear medicine functional imaging techniques as positron emission tomography (PET) and Single-photon emission computed tomography (SPECT). Medical imaging reagents play a significant role in diagnostic, pharmaceuticals, biotechnology medical and life science industries.The global medical imaging reagents market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020).The global medical imaging reagents market segmentation is based on product types (contrast reagents, optical reagents, nuclear reagents), technology (fluorescent dyes and probes, fluorescent proteins, nanoparticles, quantum dots, radiopharmaceuticals), and applications (diagnostics, drug discovery and development, research and development).The global medical imaging reagents market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global medical imaging reagents market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global medical imaging reagents market and included in this report are Bayer Healthcare AG, Bracco Imaging SpA, GE Healthcare, Lantheus Medical Imaging, Inc., Mallinckrodt Pharmaceuticals, Siemens Healthcare, Thermo Fisher Scientific, Inc. and others.To request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/medical-imaging-equipment-market/About UsiHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


NEW YORK and MELBOURNE, Australia, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into an equity purchase agreement with Mallinckrodt Pharmaceuticals and will exclusively negotiate a commercial and development partnership for two of Mesoblast's Tier 1 product candidates, MPC-06-ID in the treatment or prevention of moderate/severe chronic low back pain (CLBP) due to disc degeneration and MSC-100-IV in the treatment of acute graft versus host disease (GVHD). Under the terms of the agreement, Mallinckrodt will have an exclusive period of up to nine months to conclude commercial and development agreements for the two product candidates in all territories outside of Japan and China. As consideration, Mallinckrodt will purchase approximately 20.04 million (4.99%) of Mesoblast’s ordinary shares at a price of A$1.4761 per share. Mallinckrodt is a global specialty pharmaceutical company with a major focus within the hospital acute and critical care settings, including pain management, autoimmune and rare diseases, and specialty generic pharmaceuticals.  The company's key branded products in these areas, generating multi-billion dollar revenues, include H.P. Acthar Gel® (repository corticotrophin injection) and Therakos® Immunotherapy platform, OFIRMEV® (acetaminophen injection), and INOMAX® (nitric oxide) gas, for inhalation. Recently, Mallinckrodt has entered the regenerative medicine field with the acquisition of an investigational human keratinocyte-based regenerative medicine platform to bolster its pipeline of hospital products with an off-the-shelf skin substitute beginning Phase 3 testing for partial thickness burns. Mesoblast Chief Executive Silviu Itescu said: “We are pleased that Mallinckrodt has chosen to make an investment in Mesoblast. Mallinckrodt has a track record of success in commercializing medicines for immune-mediated diseases and pain management, and we believe that its major footprint in hospitals addressing acute care needs can be leveraged to realize the full commercial and clinical value of our innovative cellular medicines.” Steven Romano, M.D., Executive Vice President and Chief Scientific Officer of Mallinckrodt, commented: "This agreement provides Mallinckrodt with a potential opportunity to extend our regenerative medicine pipeline in areas of high unmet patient need. We see Mesoblast as a leader in developing innovative cell-based medicines and look forward to establishing a fruitful partnership." Mesoblast's product candidate MPC-06-ID is currently being evaluated in a 360-patient Phase 3 trial as a treatment for moderate/severe CLBP due to disc degeneration in patients who have failed other non-surgical options, including steroid injections and opioids. Data from 24-month follow up of 100 patients participating in a randomized, placebo-controlled Phase 2 trial of MPC-06-ID were presented in August 2016 at the 24th Annual Scientific Meeting of the Spine Intervention Society. Mesoblast's product candidate MSC-100-IV is currently being evaluated in a 60-patient open label Phase 3 trial as a front-line therapy for children with steroid-refractory acute GVHD. The trial was recently successful in a pre-specified interim futility analysis, and Mesoblast expects to fully read out trial results during 2017. Based on guidance from the United States Food and Drug Administration (FDA), Mesoblast believes that positive data from this Phase 3 trial may be sufficient for filing for accelerated approval of MSC-100-IV in the United States. Mesoblast plans to broaden the use of its therapy in adult patients with high-risk steroid-refractory acute GVHD. About Mallinckrodt Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com. About Mesoblast Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


News Article | December 5, 2016
Site: www.prnewswire.com

CHESTERFIELD, United Kingdom, Dec. 5, 2016 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it received a perfect score of 100 percent on the 2017 Corporate Equality Index (CEI), a national benchmarking...


News Article | February 24, 2017
Site: www.prnewswire.com

STAINES-UPON-THAMES, United Kingdom, Feb. 24, 2017 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, March 15, 2017, at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel, 1601...


News Article | December 15, 2016
Site: www.prnewswire.co.uk

Global Morphine Sulfat Market 2016 Research Report initially provides a basic overview of the industry that covers definition, applications and manufacturing technology, post which the report explores into the international players in the market. Browse 115 tables and figures, 09 company profiles spread across 109 pages at http://www.reportsnreports.com/reports/784845-global-morphine-sulfat-cas-64-31-3-market-research-report-2016.html . Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Morphine Sulfat in these regions, from 2011 to 2021 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Morphine Sulfat in each application. This report studies Morphine Sulfat in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Mallinckrodt Pharmaceuticals, Alcaliber, Purdue Pharma, Cepia-Sanofi, Macfarlan Smith, SUN PHARMA, Qinghai Pharmaceutical, Taj Pharmaceuticals and Northeast Pharm. Purchase a copy at http://www.reportsnreports.com/purchase.aspx?name=784845 . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers. Connect With Us On:

Loading Mallinckrodt Pharmaceuticals collaborators
Loading Mallinckrodt Pharmaceuticals collaborators